Moreover, rHuEPO, now collectively known as erythropoietin-stimulating agents (ESAs), includes recently developed long-acting products that have demonstrated significant efficacy in improving anemia, preventing complications, and improving patients’ QOL [5,6]. This evidence concerns the gene EPO and anemia.